Efficacy and Safety of Bazedoxifene in Postmenopausal Women with Osteoporosis: A Systematic Review and Meta-analysis

Overview

Journal Medicine (Baltimore)

Specialty General Medicine

Date 2017 Dec 17

PMID 29245225

Citations 13

Authors

Lihua Peng

Qian Luo

Hui Lu

Affiliations

Soon will be listed here.

Abstract

Introduction: Bazedoxifene may be promising to treat osteoporosis of postmenopausal women. We conducted a systematic review and meta-analysis to explore the efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis.

Methods: PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases were systematically searched. Randomized controlled trials (RCTs) assessing the effect of bazedoxifene on osteoporosis of postmenopausal women were included. Two investigators independently searched articles, extracted data, and assessed the quality of included studies. The primary outcomes were vertebral fracture and spine BMD at 3 and 7 years.

Results: Four RCTs are included in the meta-analysis. Overall, compared with placebo intervention in postmenopausal women with osteoporosis, bazedoxifene intervention can significantly reduce the risk of vertebral fracture [risk risks (RRs) = 0.69; 95% confidence interval (95% CI) = 0.52-0.93; P = .01], and increase spine BMD at 3 years (Std. mean difference = 1.71; 95% CI = 1.55-1.87; P < .005) and 7 years (Std. mean difference = 8.31; 95% CI = 8.07-8.55; P < .005). Bazedoxifene intervention results in no increase in adverse events (RR = 1.00; 95% CI = 0.99-1.00; P = .34), serious adverse events (RR = 1.04; 95% CI = 0.97-1.12; P = .31), myocardial infarction (RR = 0.88; 95% CI = 0.51-1.52; P = .64), stroke (RR = 0.97; 95% CI = 0.64-1.46; P = .87), venous thromboembolic event (RR = 1.56; 95% CI = 0.92-2.64; P = .10), and breast carcinoma (RR = 1.03; 95% CI = 0.59-1.79; P = .92).

Conclusions: Compared with placebo intervention for the osteoporosis of postmenopausal women, bazedoxifene intervention is found to significantly reduce the incidence of vertebral fracture and increase spine BMD at 3 and 7 years, and results in no increase in adverse events, serious adverse events, myocardial infarction, stroke, venous thromboembolic event, and breast carcinoma.

Citing Articles

Insights and implications of sexual dimorphism in osteoporosis.

Zhang Y, Xie N, Sun X, Nice E, Liou Y, Huang C Bone Res. 2024; 12(1):8.

PMID: 38368422 PMC: 10874461. DOI: 10.1038/s41413-023-00306-4.

Estrogen and psychosis - a review and future directions.

Mu E, Gurvich C, Kulkarni J Arch Womens Ment Health. 2024; 27(6):877-885.

PMID: 38221595 PMC: 11579214. DOI: 10.1007/s00737-023-01409-x.

Long-term and sequential treatment for osteoporosis.

Foessl I, Dimai H, Obermayer-Pietsch B Nat Rev Endocrinol. 2023; 19(9):520-533.

PMID: 37464088 DOI: 10.1038/s41574-023-00866-9.

Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor-Positive Breast Cancer.

Tsuji J, Li T, Grinshpun A, Coorens T, Russo D, Anderson L Clin Cancer Res. 2022; 28(23):5066-5078.

PMID: 36215125 PMC: 9722539. DOI: 10.1158/1078-0432.CCR-22-2305.

Efficacy and Safety of Postmenopausal Osteoporosis Treatments: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.

Lin S, Hung M, Chang S, Tsuang F, Chang J, Sun J J Clin Med. 2021; 10(14).

PMID: 34300210 PMC: 8305263. DOI: 10.3390/jcm10143043.

References

Silverman S, Chines A, Kendler D, Kung A, Teglbjaerg C, Felsenberg D . Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. Osteoporos Int. 2011; 23(1):351-63. DOI: 10.1007/s00198-011-1691-1. View

Atik O, Gunal I, Korkusuz F . Burden of osteoporosis. Clin Orthop Relat Res. 2006; 443:19-24. DOI: 10.1097/01.blo.0000200248.34876.fe. View

Jadad A, Moore R, Carroll D, Jenkinson C, Reynolds D, Gavaghan D . Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996; 17(1):1-12. DOI: 10.1016/0197-2456(95)00134-4. View

Park K, Lee K . Sequential subtrochanteric femoral fracture after atypical diaphyseal fracture in a long-term bisphosphonate user: a case report. Acta Chir Orthop Traumatol Cech. 2015; 82(2):157-60. View

Silverman S, Christiansen C, Genant H, Vukicevic S, Zanchetta J, de Villiers T . Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008; 23(12):1923-34. DOI: 10.1359/jbmr.080710. View

Silverman S, Kupperman E, Bukata S . Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group. Osteoporos Int. 2016; 27(7):2197-2206. DOI: 10.1007/s00198-016-3513-y. View

de Villiers T, Chines A, Palacios S, Lips P, Sawicki A, Levine A . Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. Osteoporos Int. 2010; 22(2):567-76. DOI: 10.1007/s00198-010-1302-6. View

Eastell R, Hannon R, Garnero P, Campbell M, Delmas P . Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate: review of statistical analysis. J Bone Miner Res. 2007; 22(11):1656-60. DOI: 10.1359/jbmr.07090b. View

Kjaergard L, Villumsen J, Gluud C . Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses. Ann Intern Med. 2001; 135(11):982-9. DOI: 10.7326/0003-4819-135-11-200112040-00010. View

10.

Seeman E, Delmas P . Bone quality--the material and structural basis of bone strength and fragility. N Engl J Med. 2006; 354(21):2250-61. DOI: 10.1056/NEJMra053077. View

11.

Delaney M . Strategies for the prevention and treatment of osteoporosis during early postmenopause. Am J Obstet Gynecol. 2006; 194(2 Suppl):S12-23. DOI: 10.1016/j.ajog.2005.08.049. View

12.

Lewiecki E . Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. J Womens Health (Larchmt). 2009; 18(10):1615-26. DOI: 10.1089/jwh.2008.1086. View

13.

Palacios S, Silverman S, de Villiers T, Levine A, Goemaere S, Brown J . A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Menopause. 2015; 22(8):806-13. DOI: 10.1097/GME.0000000000000419. View

14.

Shane E, Burr D, Ebeling P, Abrahamsen B, Adler R, Brown T . Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2010; 25(11):2267-94. DOI: 10.1002/jbmr.253. View

15.

Willson T, Nelson S, Newbold J, Nelson R, LaFleur J . The clinical epidemiology of male osteoporosis: a review of the recent literature. Clin Epidemiol. 2015; 7:65-76. PMC: 4295898. DOI: 10.2147/CLEP.S40966. View

16.

Bauer D, Black D, Garnero P, Hochberg M, Ott S, Orloff J . Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial. J Bone Miner Res. 2004; 19(8):1250-8. DOI: 10.1359/JBMR.040512. View

17.

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009; 339:b2535. PMC: 2714657. DOI: 10.1136/bmj.b2535. View

18.

Burger H, Dudley E, Robertson D, Dennerstein L . Hormonal changes in the menopause transition. Recent Prog Horm Res. 2002; 57:257-75. DOI: 10.1210/rp.57.1.257. View

19.

Daruwalla Z, Huq S, Wong K, Nee P, Leong K, Pillay K . Hip fractures, preceding distal radius fractures and screening for osteoporosis: should we be screening earlier? A minimum 10-year retrospective cohort study at a single centre. Osteoporos Int. 2015; 27(1):361-6. DOI: 10.1007/s00198-015-3375-8. View

20.

Noto C, Pappagallo M . Current and emerging pharmacologic therapies for pain and challenges which still lay ahead. Methods Mol Biol. 2010; 617:539-54. DOI: 10.1007/978-1-60327-323-7_39. View